We are live on ! Find out more
ABVC icon

ABVC BioPharma
ABVC

9 hedge funds and large institutions have $304K invested in ABVC BioPharma in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 9 → 9 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

0.25% less ownership

Funds ownership: 2.03% → 1.78% (-0.25%)

97% less capital inflows, than outflows

Capital inflows: $1.34K | Capital outflows: $48.6K

Holders
9
Holders Change
–
Holders Change %
0%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Spotlight Asset Group
Spotlight Asset Group
Illinois
+$665
2
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
+$419
3
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$253
4
Wells Fargo
Wells Fargo
California
+$7

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$24.5K
2
Two Sigma Securities
Two Sigma Securities
New York
-$13.5K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$8.77K
4
Two Sigma Investments
Two Sigma Investments
New York
-$1.86K

ABVC Hedge Fund Activity: Q2 2023 in Review

9 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in ABVC BioPharma (ABVC) for Q2 2023, worth a combined $304K — down 28% from $421K a quarter earlier.

Fund positioning in ABVC was balanced in Q2 2023: 2 funds opened new positions, 2 closed out, 2 added to existing stakes and 2 trimmed.

The largest buyer was Spotlight Asset Group, opening a new position worth an estimated $665. The largest seller was BlackRock, cutting an estimated $24.5K.

  • 9 institutional investors held ABVC BioPharma (ABVC) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $304K of ABVC BioPharma stock for Q2 2023, down 28% quarter-over-quarter.
  • 2 funds opened new ABVC BioPharma positions in Q2 2023 and 2 closed out, a net change of 0 holders.
  • The largest ABVC BioPharma buyer in Q2 2023 was Spotlight Asset Group, an estimated $665 added.
  • The largest ABVC BioPharma seller in Q2 2023 was BlackRock, an estimated $24.5K sold.

Based on aggregated 13F filings for Q2 2023.